Next Article in Journal
Diverse Physiological Functions of Cation Proton Antiporters across Bacteria and Plant Cells
Next Article in Special Issue
A Possible Role for Arylsulfatase G in Dermatan Sulfate Metabolism
Previous Article in Journal
Newly Identified Regulators of Ovarian Folliculogenesis and Ovulation
Previous Article in Special Issue
Targeted Metabolomic Analysis of a Mucopolysaccharidosis IIIB Mouse Model Reveals an Imbalance of Branched-Chain Amino Acid and Fatty Acid Metabolism
Open AccessReview

Neuropathophysiology, Genetic Profile, and Clinical Manifestation of Mucolipidosis IV—A Review and Case Series

1
Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland
2
Department of Medical Genetics, The Children’s Memorial Heath Institute, 04-730 Warsaw, Poland
3
Adult Inherited Metabolic Diseases, Salford Royal NHS Foundation Trust, Salford M6 8HD, UK
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2020, 21(12), 4564; https://doi.org/10.3390/ijms21124564
Received: 31 May 2020 / Revised: 21 June 2020 / Accepted: 23 June 2020 / Published: 26 June 2020
(This article belongs to the Special Issue Genetic and Metabolic Molecular Research of Lysosomal Storage Disease)
Mucolipidosis type IV (MLIV) is an ultra-rare lysosomal storage disorder caused by biallelic mutations in MCOLN1 gene encoding the transient receptor potential channel mucolipin-1. So far, 35 pathogenic or likely pathogenic MLIV-related variants have been described. Clinical manifestations include severe intellectual disability, speech deficit, progressive visual impairment leading to blindness, and myopathy. The severity of the condition may vary, including less severe psychomotor delay and/or ocular findings. As no striking recognizable facial dysmorphism, skeletal anomalies, organomegaly, or lysosomal enzyme abnormalities in serum are common features of MLIV, the clinical diagnosis may be significantly improved because of characteristic ophthalmological anomalies. This review aims to outline the pathophysiology and genetic defects of this condition with a focus on the genotype–phenotype correlation amongst cases published in the literature. The authors will present their own clinical observations and long-term outcomes in adult MLIV cases. View Full-Text
Keywords: mucolipidosis type IV; MCOLN1; corneal clouding; gastrin; myopathy; neurodegenerative mucolipidosis type IV; MCOLN1; corneal clouding; gastrin; myopathy; neurodegenerative
MDPI and ACS Style

Jezela-Stanek, A.; Ciara, E.; Stepien, K.M. Neuropathophysiology, Genetic Profile, and Clinical Manifestation of Mucolipidosis IV—A Review and Case Series. Int. J. Mol. Sci. 2020, 21, 4564. https://doi.org/10.3390/ijms21124564

AMA Style

Jezela-Stanek A, Ciara E, Stepien KM. Neuropathophysiology, Genetic Profile, and Clinical Manifestation of Mucolipidosis IV—A Review and Case Series. International Journal of Molecular Sciences. 2020; 21(12):4564. https://doi.org/10.3390/ijms21124564

Chicago/Turabian Style

Jezela-Stanek, Aleksandra; Ciara, Elżbieta; Stepien, Karolina M. 2020. "Neuropathophysiology, Genetic Profile, and Clinical Manifestation of Mucolipidosis IV—A Review and Case Series" Int. J. Mol. Sci. 21, no. 12: 4564. https://doi.org/10.3390/ijms21124564

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop